Drug Profile

JAB 23E73

Alternative Names: JAB-23E73

Latest Information Update: 26 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Jacobio Pharmaceuticals
Class Antineoplastics; Small molecules
Mechanism of Action KRAS protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I/II Solid tumours

Most Recent Events

15 May 2025 Jacobio Pharmaceuticals plans a phase I/II trial for Solid tumors (Late-stage disease, Metastatic disease) in USA (PO) in May 2025 (NCT06973564)
30 Aug 2023 Jacobio Pharmaceuticals plans to file an IND the second quarter of 2024
25 Mar 2022 JAB 23400 is available for licensing as of 25 Mar 2022. http://en.jacobiopharma.com/blank3.html?introId=23

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com